跳转至内容
Merck
CN
所有图片(1)

文件

1361009

USP

左多巴

United States Pharmacopeia (USP) Reference Standard

登录查看公司和协议定价
所有图片(1)
别名:
左旋多巴, 3-(3,4-二羟基苯基)-L-丙氨酸, 3-羟基-L-酪氨酸, L-DOPA, 左多巴
线性分子式:
(HO)2C6H3CH2CH(NH2)CO2H
CAS号:
59-92-7
分子量:
197.19
Beilstein:
2215169
MDL编号:
MFCD00002598
UNSPSC代码:
41116107
PubChem化学物质编号:
329750042
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

levodopa

制造商/商品名称

USP

mp

276-278 °C (lit.)

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O

InChI

1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

InChI key

WTDRDQBEARUVNC-LURJTMIESA-N

基因信息

human ... DRD3(1814)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Levodopa USP Reference standard for use in specified quality tests and assays.

Also used to prepare standard and system suitability solution during the assay, performance test, and impurity analysis by using liquid chromatography in conjunction with UV detectors in accordance with the given below monographs of United States Pharmacopeia (USP) :
  • Levodopa
  • Carbidopa and Levodopa Orally Disintegrating Tablets
  • Carbidopa and Levodopa Tablets
  • Carbidopa and Levodopa Extended-Release Tablets

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险分类

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Carbidopa and Levodopa Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 47(5) (2022)
Carbidopa and Levodopa Orally Disintegrating Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 44(1), 759-759 (2022)
Carbidopa and Levodopa Extended-Release Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(3), 753-753 (2018)
Levodopa
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(1), 2604-2604 (2020)
Nicolas Morin et al.
Experimental neurology, 256, 105-116 (2013-01-31)
The treatment of motor symptoms of Parkinson disease (PD) with the dopamine (DA) precursor, l-3,4-dihydroxyphenylalanine (l-DOPA) introduced 50years ago still remains a very effective medication. However, involuntary movements termed l-DOPA-induced dyskinesias (LID) appear in the vast majority of PD patients
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门